Aptevo Therapeutics (APVO) vs Mustang Bio (MBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aptevo Therapeutics is the larger company by market cap ($3.3 million vs $3.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APVO | MBIO |
|---|---|---|
| Share price | $1.80 | $0.417 |
| Market cap | $3.26M | $3.16M |
| 1-day change | -2.17% | -7.37% |
| P/E ratio (TTM) | 0.03 | — |
| EPS (TTM) | $66.96 | $-0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.14 | $1.81 |
| 52-week low | $1.37 | $0.41 |
| Distance from 52-week high | -94.22% | -76.96% |
| Analyst consensus | none | — |
| Avg. price target upside | +1316.67% | — |
| Average volume | 91.51K | 29.38K |
| Shares outstanding | 1.81M | 6.73M |
| Employees | 33 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aptevo Therapeutics
APVO stock →Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Healthcare · Biotechnology · 33 employees
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Healthcare · Biotechnology · 4 employees
APVO vs MBIO FAQ
Which is bigger, Aptevo Therapeutics or Mustang Bio?
Aptevo Therapeutics (APVO) is larger, with a market capitalization of $3.26M compared with $3.16M for Mustang Bio (MBIO).
Are Aptevo Therapeutics and Mustang Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.